Journal article
No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide
Expert review of anticancer therapy, Vol.14(10), pp.1135-1140
10/01/2014
DOI: 10.1586/14737140.2014.949677
PMID: 25135334
Abstract
Prostate cancer is the second leading cause of cancer-related deaths in men in most western countries. New agents for metastatic castration-resistant prostate cancer (CRPC) developed in the past 3 years include abiraterone acetate (AA) and enzalutamide (ENZ), which inhibit signaling by and synthesis of androgens, respectively. Because they share the same target, potential clinical cross-resistance between AA and E is possible. In this review, we discuss the results of clinical studies in which CRPC patients were treated with AA and E either separately or in sequence after first-line treatment with docetaxel. Our review suggests that sequential administration of AA and E in either order has limited activity after docetaxel therapy. Prospective studies that further examine sequential treatments with AA and E are warranted.
Details
- Title: Subtitle
- No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide
- Creators
- Edoardo Francini - Policlinico Umberto IRoberto Petrioli - University of SienaGiandomenico Roviello - University of Siena
- Resource Type
- Journal article
- Publication Details
- Expert review of anticancer therapy, Vol.14(10), pp.1135-1140
- DOI
- 10.1586/14737140.2014.949677
- PMID
- 25135334
- ISSN
- 1473-7140
- eISSN
- 1744-8328
- Publisher
- Taylor & Francis
- Number of pages
- 6
- Language
- English
- Date published
- 10/01/2014
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221243402771
Metrics
1 Record Views